Bim deletion polymorphism was significantly associated with the clinical efficacy of tyrosine kinase inhibitors in terms of response rate and disease control rate in EGFR-mutated NSCLC patients, but not in CML or hepatocellular carcinoma (HCC) [639]. Here, BCL2L11 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.